CD274 and non-small cell lung carcinoma: The phase II IFCT-IONESCO study was designed to evaluate the feasibility of the anti-PD-L1 agent durvalumab as a neoadjuvant therapy in 46 resectable patients with stage IB-IIIA NSCLC [11].